中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

经肝动脉化疗栓塞术联合干扰素治疗中晚期原发性肝癌疗效的Meta分析

翁柠娜 李肖

翁柠娜, 李肖. 经肝动脉化疗栓塞术联合干扰素治疗中晚期原发性肝癌疗效的Meta分析[J]. 临床肝胆病杂志, 2016, 32(1): 76-79. DOI: 10.3969/j.issn.1001-5256.2016.01.012
引用本文: 翁柠娜, 李肖. 经肝动脉化疗栓塞术联合干扰素治疗中晚期原发性肝癌疗效的Meta分析[J]. 临床肝胆病杂志, 2016, 32(1): 76-79. DOI: 10.3969/j.issn.1001-5256.2016.01.012
Weng NingNa, Li Xiao. Effect of transcatheter arterial chemoembolization combined with interferon adjuvant therapy in treatment of advanced primary liver cancer: a meta-analysis[J]. J Clin Hepatol, 2016, 32(1): 76-79. DOI: 10.3969/j.issn.1001-5256.2016.01.012
Citation: Weng NingNa, Li Xiao. Effect of transcatheter arterial chemoembolization combined with interferon adjuvant therapy in treatment of advanced primary liver cancer: a meta-analysis[J]. J Clin Hepatol, 2016, 32(1): 76-79. DOI: 10.3969/j.issn.1001-5256.2016.01.012

经肝动脉化疗栓塞术联合干扰素治疗中晚期原发性肝癌疗效的Meta分析

DOI: 10.3969/j.issn.1001-5256.2016.01.012
详细信息
  • 中图分类号: R735.7

Effect of transcatheter arterial chemoembolization combined with interferon adjuvant therapy in treatment of advanced primary liver cancer: a meta-analysis

  • 摘要:

    目的评价干扰素(IFN)辅助经肝动脉化疗栓塞术(TACE)治疗中晚期原发性肝癌患者的疗效,为TACE术后辅助治疗提供思路。方法利用计算机检索Cochrane图书馆、Pub Med、Medline、Embase、CNKI、万方、维普等数据库2015年1月以前的文献,纳入所有国内外期刊公开发表的关于TACE联合IFN对比TACE单独治疗中晚期原发性肝癌的随机对照试验。对纳入文献进行质量评价和资料提取,采用Revman 5.1软件进行Meta分析。结果共纳入6篇文献,包括IFN辅助治疗组311例和安慰剂组308例患者。分析结果显示,IFN辅助治疗组的1、2、3年复发率均比安慰剂组低,1年生存率比安慰剂组高,差异均有统计学意义(P值分别为0.006、0.002、0.002、0.030)。结论 IFN辅助治疗能降低TACE术后肝癌的复发风险,提高患者的生存率。

     

  • [1]FORNER A,LLOVET JM,BRUIX J,et al.Hepatocellular carcinoma[J].Lancet,2012,379(9822):1245-1255.
    [2]BRUIX J,SHERMAN M.Management of hepatocellular carcinoma:an update[J].Hepatology,2011,53(3):1020-1022.
    [3]IKEDA K,KOBAYASHI M,SEKO Y,et al.Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation:a retrospective study of hepatitis C virus-related liver cancer[J].Hepatol Res,2010,40(12):1168-1175.
    [4]JIANG S,LIU Y,WANG L,et al.A meta-analysis and systematic review:adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma[J].World J Surg Oncol,2013,11:240.
    [5]ZHUANG L,ZENG X,YANG Z,et al.Effect and safety of interferon for hepatocellular carcinoma:a systematic review and metaanalysis[J].PLoS One,2013,8(9):e61361.
    [6]LIN SM,LIN CJ,HSU CW,et al.Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors[J].Cancer,2004,100(2):376-382.
    [7]LI M,LU C,CHENG J,et al.Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma[J].J Gastroenterol Hepatol,2009,24(8):1437-1444.
    [8]CAI ZH,ZHENG NY,WANG BR.Clinical effect of transarterial chemoembolization and interferon therapy for advanced liver cancer[J].Guide China Med,2011,9(34):354-355.(in Chinese)蔡植华,郑乃莹,王碧荣.肝动脉栓塞化疗与干扰素治疗中晚期肝癌的临床疗效研究[J].中国医药指南,2011,9(34):354-355.
    [9]GAO J,LI XS,SHEN W,et al.Therapeutic effect and prognosis of interferon therapy after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma associated with hepatitis B virus[J].Chin J Hepatol,2004,12(8):460-462.(in Chinese)高建,李孝生,沈薇,等.干扰素联合肝动脉化疗栓塞治疗HBsA g阳性的肝癌患者疗效和预后探讨[J].中华肝脏病杂志,2004,12(8):460-462.
    [10]WANG YR,SONG SH.Clinical effect of interferon-αas adjuvant therapy for advanced primary liver cancer[J].Mod J Integr Tradit Chin West Med,2014,23(12):1317-1318.(in Chinese)王屹然,宋苏华.干扰素-α辅助治疗原发性肝癌晚期临床观察[J].现代中西医结合杂志,2014,23(12):1317-1318.
    [11]LI HH,WANG J,DUAN ZH,et al.The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrenc[J].Chin J Oncol,2004,26(9):558-561.(in Chinese)黎洪浩,王捷,段朝晖,等.干扰素联合肝动脉化疗栓塞和门静脉化疗对预防肝癌切除术后复发的价值[J].中华肿瘤杂志,2004,26(9):558-561.
    [12]LLOVET JM,BRUIX J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival[J].Hepatology,2003,37(2):429-442.
    [13]XIAO L,WANG M.Batimastat nanoparticles associated with transcatheter arterial chemoembolization decrease hepatocellular carcinoma recurrence[J].Cell Biochem Biophys,2014,70(1):269-272.
    [14]KUSANO H,AKIBA J,OGASAWARA S,et al.Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo[J].PLoS One,2013,8(12):e83195.
    [15]XU JB,QI FZ,XU G,et al.Adjuvant interferon therapy after surgical treatment for hepatitis B/C virus-related hepatocellular carcinoma:a meta-analysis[J].Hepatol Res,2014,44(2):209-217.
    [16]LI DK,CHUNG RT.Impact of hepatitis C virus eradication on hepatocellular carcinogenesis[J].Cancer,2015,121(17):2874-2882.
    [17]MOON C,JUNG KS,KIM DO Y,et al.Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin[J].Dig Dis Sci,2015,60(2):573-581.
    [18]WANG L,TANG ZY,QIN LX,et al.High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential[J].Hepatology,2000,32(1):43-48.
    [19]THOMPSON MD,DAR MJ,MONGA SP.Pegylated interferon alpha targets Wnt signaling by inducing nuclear export ofβ-catenin[J].J Hepatol,2011,54(3):506-512.
    [20]MAEDA S,WADA H,NAITO Y,et al.Interferon-αacts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line[J].J Biol Chem,2014,289(34):23786-23795.
  • 加载中
计量
  • 文章访问数:  1401
  • HTML全文浏览量:  5
  • PDF下载量:  403
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-11-26
  • 刊出日期:  2016-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回